NEW YORK — Apr 21, 2020 — Acuamark Diagnostics, Inc. (“AcuamarkDx”), a biotechnology company that focuses on developing innovative blood-based screening assays for reliable and cost-effective detection of early-stage cancer, today announced the appointment of William Gedale as its Executive Chairman. Mr. Gedale will replace Mr. Michael...

NEW YORK — Dec 27, 2019 — Acuamark Diagnostics, Inc. (“Acuamark”), a biotechnology company that focuses on developing innovative blood-based screening assays for reliable and cost-effective detection of early-stage cancer, today announced that it has completed private placement of its Preferred Series AA3 stock in a round that was subs...

TAMPA, Fla., Dec. 13, 2016 /PRNewswire/ -- The National Academy of Inventors (NAI) has named 175 leaders of academic invention to NAI Fellow status.

In its early stages, cancer is usually asymptomatic. Early detection is a complex challenge. Can a blood sample detect early signs?

NEW YORK (GenomeWeb) – Last month, iCareDx announced that it was rebranding itself as Acuamark Diagnostics as it works to raise funds for its first round of clinical testing.

Globally, over 22,000 people die of cancer each day. When cancer is detected at the early stages, survival rates are generally still high. Finding cancer early with an accurate, convenient and affordable technology, and attacking it early, can vastly reduce cancer deaths, and substantially lower cancer-related healthcare expenditures.